IL-7 and IL-15 bypass the immunosuppressive action of anti-CD25 monoclonal antibodies

Transplant Proc. 2001 May;33(3):2244-6. doi: 10.1016/s0041-1345(01)01954-6.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Monoclonal / pharmacology*
  • Antibodies, Monoclonal, Humanized
  • Basiliximab
  • Cells, Cultured
  • Daclizumab
  • Dose-Response Relationship, Drug
  • Humans
  • Immunoglobulin G / pharmacology*
  • Immunosuppressive Agents / pharmacology*
  • Interleukin-15 / pharmacology*
  • Interleukin-2 / pharmacology
  • Interleukin-7 / pharmacology*
  • Kinetics
  • Lymphocyte Activation / drug effects
  • Lymphocyte Activation / immunology*
  • Lymphocytes / drug effects
  • Lymphocytes / immunology*
  • Mice
  • Receptors, Interleukin-2 / immunology*
  • Recombinant Fusion Proteins*
  • Recombinant Proteins / pharmacology

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Immunoglobulin G
  • Immunosuppressive Agents
  • Interleukin-15
  • Interleukin-2
  • Interleukin-7
  • Receptors, Interleukin-2
  • Recombinant Fusion Proteins
  • Recombinant Proteins
  • Basiliximab
  • Daclizumab
  • inolimomab